36.52
price down icon1.62%   -0.60
after-market 시간 외 거래: 36.54 0.02 +0.05%
loading
전일 마감가:
$37.12
열려 있는:
$37.49
하루 거래량:
2.65M
Relative Volume:
2.75
시가총액:
$3.55B
수익:
$522.75M
순이익/손실:
$-558.99M
주가수익비율:
-5.6445
EPS:
-6.47
순현금흐름:
$-439.53M
1주 성능:
-1.67%
1개월 성능:
+4.10%
6개월 성능:
-15.89%
1년 성능:
-11.83%
1일 변동 폭
Value
$35.59
$38.19
1주일 범위
Value
$35.59
$38.19
52주 변동 폭
Value
$29.59
$60.37

울트라제닉스 파마슈티컬 Stock (RARE) Company Profile

Name
명칭
Ultragenyx Pharmaceutical Inc
Name
전화
415-483-8800
Name
주소
60 LEVERONI COURT, NOVATO, CA
Name
직원
1,294
Name
트위터
Name
다음 수익 날짜
2024-11-05
Name
최신 SEC 제출 서류
Name
RARE's Discussions on Twitter

RARE을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
RARE
Ultragenyx Pharmaceutical Inc
36.52 3.55B 522.75M -558.99M -439.53M -6.47
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
441.30 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
521.00 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
322.83 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
560.14 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
241.20 28.51B 3.81B -644.79M -669.77M -6.24

울트라제닉스 파마슈티컬 Stock (RARE) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-05-28 개시 William Blair Outperform
2024-06-06 업그레이드 Goldman Neutral → Buy
2024-04-22 개시 RBC Capital Mkts Outperform
2023-12-08 개시 Wells Fargo Overweight
2023-06-14 재개 Credit Suisse Outperform
2023-06-06 업그레이드 Evercore ISI In-line → Outperform
2023-04-26 개시 Cantor Fitzgerald Overweight
2023-01-18 재개 Canaccord Genuity Buy
2022-12-30 재개 H.C. Wainwright Buy
2022-11-03 업그레이드 Robert W. Baird Neutral → Outperform
2022-10-13 업그레이드 Guggenheim Neutral → Buy
2022-08-01 다운그레이드 Evercore ISI Outperform → In-line
2022-03-16 업그레이드 Credit Suisse Neutral → Outperform
2022-02-11 업그레이드 JP Morgan Neutral → Overweight
2021-09-30 개시 H.C. Wainwright Buy
2021-08-19 개시 UBS Sell
2021-07-15 개시 Guggenheim Neutral
2021-06-29 업그레이드 BofA Securities Neutral → Buy
2021-06-04 재개 Robert W. Baird Neutral
2021-05-06 업그레이드 Citigroup Neutral → Buy
2021-05-06 업그레이드 Evercore ISI In-line → Outperform
2021-04-26 재개 Credit Suisse Neutral
2021-03-02 재개 Stifel Buy
2021-02-12 다운그레이드 JP Morgan Overweight → Neutral
2020-12-07 다운그레이드 Wedbush Outperform → Neutral
2020-11-24 재개 Evercore ISI In-line
2020-11-12 다운그레이드 BofA Securities Buy → Neutral
2019-08-02 재개 Wedbush Outperform
2019-03-27 업그레이드 Morgan Stanley Equal-Weight → Overweight
2019-02-22 재개 Raymond James Outperform
2019-01-02 다운그레이드 Raymond James Outperform → Mkt Perform
2018-11-08 업그레이드 Citigroup Sell → Neutral
2018-09-10 개시 Morgan Stanley Equal-Weight
2018-06-21 다운그레이드 Credit Suisse Outperform → Neutral
2018-05-11 업그레이드 Barclays Equal Weight → Overweight
2018-05-10 개시 Goldman Neutral
2018-04-18 업그레이드 SunTrust Hold → Buy
2018-03-22 재개 Piper Jaffray Overweight
2018-02-21 재확인 Stifel Buy
2018-01-22 업그레이드 Evercore ISI In-line → Outperform
2018-01-18 개시 Credit Suisse Outperform
2017-12-05 재확인 Barclays Equal Weight
2017-12-04 업그레이드 Jefferies Hold → Buy
2017-09-14 업그레이드 Wedbush Neutral → Outperform
모두보기

울트라제닉스 파마슈티컬 주식(RARE)의 최신 뉴스

pulisher
Jun 18, 2025

Exploring the Road Ahead: X-linked Hypophosphatemia Market - openPR.com

Jun 18, 2025
pulisher
Jun 16, 2025

(RARE) Long Term Investment Analysis - news.stocktradersdaily.com

Jun 16, 2025
pulisher
Jun 14, 2025

Ultragenyx’s SWOT analysis: rare disease biotech stock faces pivotal year By Investing.com - Investing.com Canada

Jun 14, 2025
pulisher
Jun 14, 2025

Ultragenyx’s SWOT analysis: rare disease biotech stock faces pivotal year - Investing.com Australia

Jun 14, 2025
pulisher
Jun 13, 2025

FDA approves Ultragenyx's Mepsevii in mucopolysaccharidosis type VII enzyme disorder - FirstWord Pharma

Jun 13, 2025
pulisher
Jun 10, 2025

Transcript : Ultragenyx Pharmaceutical Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 10 - MarketScreener

Jun 10, 2025
pulisher
Jun 09, 2025

Ultragenyx (RARE) Q1 2025 Performance Shows Resilience - GuruFocus

Jun 09, 2025
pulisher
Jun 05, 2025

Ultragenyx reports 28% rise in Q1 revenue from year ago - The Press Democrat

Jun 05, 2025
pulisher
Jun 05, 2025

Ultragenyx (RARE) Up 9.6% Since Last Earnings Report: Can It Continue? - Yahoo Finance

Jun 05, 2025
pulisher
Jun 04, 2025

Mucopolysaccharidosis III Pipeline 2025: Groundbreaking - openPR.com

Jun 04, 2025
pulisher
Jun 04, 2025

How the (RARE) price action is used to our Advantage - news.stocktradersdaily.com

Jun 04, 2025
pulisher
Jun 03, 2025

Ultragenyx to Participate at Goldman Sachs 46th Annual Global He - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Ultragenyx to Participate at Goldman Sachs 46th Annual Global Healthcare Conference | RARE Stock News - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Ultragenyx to Participate at Goldman Sachs 46th Annual Global Healthcare Conference - GlobeNewswire

Jun 03, 2025
pulisher
Jun 03, 2025

Ultragenyx CEO Reveals Latest Rare Disease Breakthroughs at Goldman Sachs Healthcare Conference - Stock Titan

Jun 03, 2025
pulisher
May 29, 2025

Adeno-Associated Virus (AAV) Vectors in Gene Therapy Pipeline - openPR.com

May 29, 2025
pulisher
May 29, 2025

William Blair Initiates Coverage of Ultragenyx Pharmaceutical (BMV:RARE) with Outperform Recommendation - Nasdaq

May 29, 2025
pulisher
May 29, 2025

Ultragenyx Pharmaceutical (NASDAQ:RARE) Coverage Initiated by Analysts at William Blair - Defense World

May 29, 2025
pulisher
May 28, 2025

William Blair Initiates Coverage of Ultragenyx Pharmaceutical (LSE:0LIF) with Outperform Recommendation - Nasdaq

May 28, 2025
pulisher
May 28, 2025

William Blair Initiates Coverage of Ultragenyx Pharmaceutical (RARE) with Outperform Recommendation - MSN

May 28, 2025
pulisher
May 28, 2025

William Blair sets Ultragenyx stock at Outperform with $65 target By Investing.com - Investing.com Australia

May 28, 2025
pulisher
May 28, 2025

What 4 Analyst Ratings Have To Say About Ultragenyx Pharmaceutical - Benzinga

May 28, 2025
pulisher
May 28, 2025

Analyst Bullish On Ultragenyx, Poised For Growth With Six Drug Approvals Expected By 2028 - Benzinga

May 28, 2025
pulisher
May 28, 2025

Ultragenyx Pharmaceutical (RARE) Receives New Coverage with 'Out - GuruFocus

May 28, 2025
pulisher
May 28, 2025

Ultragenyx Pharmaceutical (RARE) Receives New Coverage with 'Outperform' Rating | RARE Stock News - GuruFocus

May 28, 2025
pulisher
May 28, 2025

William Blair Initiates Ultragenyx Pharmaceutical at Outperform - marketscreener.com

May 28, 2025
pulisher
May 28, 2025

William Blair sets Ultragenyx stock at Outperform with $65 target - Investing.com

May 28, 2025
pulisher
May 28, 2025

Ultragenyx (RARE) Gains Outperform Rating with $65 Target | RARE Stock News - GuruFocus

May 28, 2025
pulisher
May 26, 2025

Sanfilippo syndrome Pipeline 2025: Groundbreaking Clinical - openPR.com

May 26, 2025
pulisher
May 25, 2025

Ultragenyx’s SWOT analysis: rare disease biotech stock poised for growth By Investing.com - Investing.com Nigeria

May 25, 2025
pulisher
May 25, 2025

Ultragenyx’s SWOT analysis: rare disease biotech stock poised for growth - Investing.com

May 25, 2025
pulisher
May 21, 2025

CDKL5 Deficiency Disorder Market Expected to Experience Major - openPR.com

May 21, 2025
pulisher
May 21, 2025

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

May 21, 2025
pulisher
May 20, 2025

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 56 - GuruFocus

May 20, 2025
pulisher
May 20, 2025

Ultragenyx Grants $4.5M in Stock Awards: 20 New Hires Receive Retention Packages - Stock Titan

May 20, 2025
pulisher
May 20, 2025

Ultragenyx Pharmaceutical Approves Key Proposals at Annual Meeting - MSN

May 20, 2025
pulisher
May 14, 2025

Ultragenyx Underscores Continued Commitment to Rare Disease Inno - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Ultragenyx Underscores Continued Commitment to Rare Disease Innovation with 2024 Impact Report - GlobeNewswire

May 14, 2025
pulisher
May 14, 2025

Ultragenyx Underscores Continued Commitment to Rare Disease Innovation with 2024 Impact Report | RARE Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

(RARE) Technical Pivots with Risk Controls - news.stocktradersdaily.com

May 14, 2025
pulisher
May 13, 2025

Transcript : Ultragenyx Pharmaceutical Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 08 - marketscreener.com

May 13, 2025
pulisher
May 12, 2025

Glycogen Storage Disease Treatment Market Size in 7MM - openPR.com

May 12, 2025

울트라제닉스 파마슈티컬 (RARE) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$20.50
price down icon 1.11%
$35.87
price up icon 1.70%
$20.60
price down icon 3.38%
$99.49
price down icon 2.21%
$106.72
price up icon 0.55%
biotechnology ONC
$241.20
price down icon 5.22%
자본화:     |  볼륨(24시간):